Dermatologic Toxicities Associated with Tebentafusp for Uveal Melanoma: A Review of Clinical Trials and Real-World Evidence

Abstract

Simple Summary Tebentafusp is a novel therapy and the first treatment shown to improve survival in patients with advanced uveal melanoma. Because it directs the immune system against a protein that is also found on normal pigment-producing cells in the skin, skin-related side effects are common, particularly rash and itching. In this review, we summarize the current evidence on these cutaneous reactions from both clinical trials and real-world clinical practice, including their frequency, presentation, management, and potential relationship with treatment outcomes. Most skin reactions are mild, occur early during treatment, and can be effectively managed without discontinuing therapy. Recognizing and appropriately treating these side effects is therefore important to help patients safely continue tebentafusp and benefit from its life-prolonging effects.